drugset / Trial / NCT05890521
Safety Study of COVID19 Vaccine on the Market
Phase 4
Unknown
100000 enrolled
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Guizhou Center for Disease Control and Prevention · collabHainan Center for Disease Control & Prevention · collabHunan Provincial Center for Disease Control and Prevention · collab
NaSingle-groupOpen-labelPrevention
Summary
Popular topic:Multi-center safety observation of recombinant Novel Coronavirus protein vaccine (CHO cells) in a large population Study population:People aged 18 and above
Timeline
- Start
- 2022-04-02
- Primary completion
- 2022-06-16
- Completion
- 2023-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Recombinant new coronavirus vaccine (CHO cell) | Vaccine | 0.5 ml | Intramuscular |